News headlines about PAREXEL International (NASDAQ:PRXL) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. PAREXEL International earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 46.744256822739 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
PAREXEL International (NASDAQ PRXL) remained flat at $$88.08 on Friday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.45 and a quick ratio of 1.45. PAREXEL International has a fifty-two week low of $51.16 and a fifty-two week high of $88.10.
PAREXEL International (NASDAQ:PRXL) last released its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. The company had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International had a net margin of 4.62% and a return on equity of 19.95%. During the same quarter in the previous year, the company earned $0.94 EPS.
Separately, Zacks Investment Research upgraded shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a research note on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. PAREXEL International currently has an average rating of “Hold” and an average price target of $80.76.
TRADEMARK VIOLATION NOTICE: “PAREXEL International (PRXL) Given Daily Coverage Optimism Score of 0.14” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://transcriptdaily.com/2017/11/26/parexel-international-prxl-given-daily-coverage-optimism-score-of-0-14.html.
PAREXEL International Company Profile
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.
Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.